Integrated DNA Technologies and Aldevron Launch New Cas9 mRNA Solutions to Accelerate Path from Gene Editing Research to Development

IDT and Aldevron introduce co-developed Cas9 mRNA tools designed to streamline CRISPR gene editing programs from research toward CGMP-ready development.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Co-developed offering connects Integrated DNA Technologies’ CRISPR engineering and analysis expertise with Aldevron’s mRNA manufacturing capabilities, helping customers move from discovery toward clinical development with greater speed, continuity, and confidence.
• Research grade S.p. Cas9 mRNA is available in wild type and SpyFi™ high-fidelity formats to support CRISPR-based research applications.
• Optimized mRNA constructs are designed for high on-target editing, reduced off-target activity with SpyFi, low toxicity, and delivery method flexibility.

Integrated DNA Technologies and Aldevron announce the launch of research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats for CRISPR-based genome editing research. The co-developed offering combines IDT’s CRISPR engineering expertise with Aldevron’s mRNA manufacturing capabilities to provide researchers with optimized Cas9 mRNA designed for high on-target editing, reduced off-target activity with SpyFi™, and compatibility with multiple delivery methods.

“Gene editing researchers are under pressure to move faster without compromising performance, reproducibility, or flexibility,” said Christopher Vakulskas, senior director, applied science and molecular design at Integrated DNA Technologies. “By connecting IDT’s CRISPR protein engineering expertise, with Aldevron’s mRNA manufacturing capabilities, scientists will now have access to an optimized Cas9 mRNA offering designed to support efficient editing, reduced off-target risk, and greater continuity as their programs advance. It’s a strong example of how connected expertise across Danaher companies can help researchers reduce complexity and move promising science forward with greater speed and confidence.”

As gene editing advances toward clinically relevant ex vivo and in vivo applications, customers need CRISPR mRNA reagents that deliver reproducible editing performance, reduce technical risk, support emerging delivery approaches, and fit into programs that may ultimately need to scale. IDT and Aldevron’s co-developed Cas9 mRNA directly addresses these challenges through optimized constructs manufactured in consistent research grade formats, with a path to scaled CGMP-manufactured versions as programs progress.

Addressing a critical need in translational gene editing

The new offering is designed to support high on-target editing efficiency across multiple cell types, including T cells, iPSCs, and immortalized cells, while the SpyFi high-fidelity version helps reduce off-target editing risk. The mRNA formats are compatible with delivery via electroporation, cationic lipids, and lipid nanoparticles (LNP), giving customers flexibility to select the approach that best fits their application.

The Cas9 mRNA is enzymatically capped, providing customers with a high-performing alternative to certain proprietary capping technologies. By reducing licensing burden and simplifying access, the offering helps researchers focus on advancing their science rather than managing licensing complexity.

Creating a more connected path from discovery to development

By introducing Cas9 mRNA as part of a broader IDT and Aldevron gene editing workflow, the companies are expanding the options available to customers who need reliable, high-performance research tools, scientific support, and continuity across CRISPR design, analysis, RNA manufacturing, and future scale-up. This launch is the first in a suite of co-developed offerings, with base and prime editors slated later this year.

With a rich history of working together to provide customers with critical tools and manufacturing support for genomic medicine workflows, IDT and Aldevron are building on that foundation to equip customers with a new mRNA modality option for Cas9-based gene editing. The solution combines IDT’s guide RNA design and analysis expertise and Aldevron’s mRNA manufacturing capabilities—the result is a streamlined experience for customers advancing Cas9-based gene editing programs from early research through CGMP manufacturing.

Visit www.idtdna.com/Cas9mRNA for product ordering, availability, and additional details.

Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; Aldevron provides Research Grade (RG) and Current Good Manufacturing Practice (CGMP) products. RUO and RG products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD and CGMP products are intended for diagnostic or clinical applications as specified in product documentation. References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.

About Aldevron

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.

About IDT

Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916928591/en/

Media Contacts:
Aldevron
Ellen Shafer
Senior Director of Communications Director
ellen.shafer@aldevron.com
(701) 219-0333

Integrated DNA Technologies
Kristina Sarenas
Public Relations
ksarenas@idtdna.com
(714) 213-9468

Source: Integrated DNA Technologies

Key Terms

cas9 mrna technical

Cas9 mRNA is the messenger RNA that carries the genetic instructions for making the Cas9 protein, the DNA-cutting enzyme used in CRISPR gene-editing systems. Delivered into cells, the mRNA is translated into Cas9 protein which, guided by a separate RNA, makes precise cuts in DNA — like sending a blueprint to build a pair of molecular scissors for a specific address. Investors track Cas9 mRNA because it is a key technical and manufacturing component in gene‑editing therapies, influencing development timelines, regulatory considerations, production complexity, and intellectual property value.

crispr technical

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

cgmp regulatory

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

lnp technical

LNP stands for lipid nanoparticle, a tiny fatty-particle carrier used to deliver medicines like RNA therapies into cells. Think of it as a microscopic delivery van that protects fragile drug cargo on the way to its destination; for investors, LNP technology matters because it affects a therapy’s effectiveness, safety, manufacturing complexity and intellectual property value, all of which influence a drug candidate’s commercial prospects and regulatory risk.

ipscs medical

Induced pluripotent stem cells (iPSCs) are ordinary adult cells that scientists have 'reset' into a flexible, stem‑like state so they can be turned into many different cell types — think of restoring a phone to factory settings so it can run new apps. They matter to investors because iPSCs are used to test drugs, model diseases and develop cell therapies, offering potential cost and time savings but also carrying technical, safety and regulatory risks that affect commercial value.